247 related articles for article (PubMed ID: 37124368)
21. Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study.
Sivridaş M; Creemers RH; Wong DR; Boekema PJ; Römkens TEH; Gilissen LPL; van Bodegraven AA; Loeff FC; Rispens T; Derijks LJJ
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986833
[TBL] [Abstract][Full Text] [Related]
22. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
Jossen J; Kiernan BD; Pittman N; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):304-309. PubMed ID: 31738290
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Visuri I; Eriksson C; Karlqvist S; Lykiardopoulos B; Karlén P; Grip O; Söderman C; Almer S; Hertervig E; Marsal J; Malmgren C; Delin J; Strid H; Sjöberg M; Bergemalm D; Hjortswang H; Halfvarson J
Therap Adv Gastroenterol; 2023; 16():17562848231174953. PubMed ID: 37274297
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels.
Hüttemann E; Muzalyova A; Gröhl K; Nagl S; Fleischmann C; Ebigbo A; Classen J; Wanzl J; Prinz F; Mayr P; Schnoy E
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202147
[TBL] [Abstract][Full Text] [Related]
26. P042 Early Versus Later Use of Vedolizumab In IBD: Patient Characteristics And Treatment Patterns In The Real World (RALEE).
Kuharic M; Krugliak Cleveland N; Candela N; Carter J; Qian J; Rusibamayila N; Turpin R; Rubin D
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11. PubMed ID: 37461960
[TBL] [Abstract][Full Text] [Related]
27. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
[TBL] [Abstract][Full Text] [Related]
30. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
[TBL] [Abstract][Full Text] [Related]
31. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Lin WC; Tai WC; Chang CH; Tu CH; Feng IC; Shieh MJ; Chung CS; Yen HH; Chou JW; Wong JM; Liu YH; Huang TY; Chuang CH; Tsai TJ; Chiang FF; Lu CY; Hsu WH; Yu FJ; Chao TH; Wu DC; Ho AS; Lin HH; Feng CL; Wu KL; Wong MW; Tung CC; Lin CC; Chen CC; Hu HM; Lu LS; Wang HS; Wu IC; Kuo HY; Wu JF; Yao Shih H; Ni YH; Tang SL; Chen PH; Wei SC
Inflamm Bowel Dis; 2023 Nov; 29(11):1730-1740. PubMed ID: 36626567
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.
Kuo CJ; Le PH; Tai WC; Wu KL; Yen HH; Yen CW; Tung SY; Chung CS; Su MY; Chiu CT
J Formos Med Assoc; 2022 Sep; 121(9):1689-1695. PubMed ID: 34924273
[TBL] [Abstract][Full Text] [Related]
33. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of probiotics in the induction and maintenance of inflammatory bowel disease remission: a systematic review and meta-analysis.
Chen M; Feng Y; Liu W
Ann Palliat Med; 2021 Nov; 10(11):11821-11829. PubMed ID: 34872306
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
36. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
[TBL] [Abstract][Full Text] [Related]
37. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
[TBL] [Abstract][Full Text] [Related]
39. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Medvedeva E; Xie D; Yang YX
Inflamm Bowel Dis; 2022 May; 28(5):734-744. PubMed ID: 34245261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
